Groupama Asset Managment Takes $19.52 Million Position in Haemonetics Co. (NYSE:HAE)

Groupama Asset Managment acquired a new position in shares of Haemonetics Co. (NYSE:HAE) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 250,000 shares of the medical instruments supplier’s stock, valued at approximately $19,520,000.

Several other institutional investors have also recently modified their holdings of HAE. FMR LLC raised its position in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after buying an additional 521,640 shares during the last quarter. Norges Bank acquired a new stake in shares of Haemonetics during the fourth quarter worth $32,803,000. Wellington Management Group LLP grew its position in shares of Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the period. Raymond James Financial Inc. purchased a new position in Haemonetics during the fourth quarter worth about $19,002,000. Finally, Thrivent Financial for Lutherans boosted its stake in Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after buying an additional 164,111 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Trading Up 0.7 %

NYSE HAE opened at $63.65 on Tuesday. The company’s fifty day simple moving average is $65.85 and its 200-day simple moving average is $74.63. The stock has a market cap of $3.20 billion, a P/E ratio of 25.06, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the topic of several recent analyst reports. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities dropped their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.